Literature DB >> 16280439

Pulmonary cachexia, systemic inflammatory profile, and the interleukin 1beta -511 single nucleotide polymorphism.

Roelinka Broekhuizen1, Robert F Grimble, W Martin Howell, Dennis J Shale, Eva C Creutzberg, Emiel F Wouters, Annemie M Schols.   

Abstract

BACKGROUND: Cachexia is common in chronic obstructive pulmonary disease (COPD) and is thought to be linked to an enhanced systemic inflammatory response.
OBJECTIVE: We investigated differences in the systemic inflammatory profile and polymorphisms in related inflammatory genes in COPD patients.
DESIGN: A cross-sectional study was performed in 99 patients with COPD (Global Initiative for Chronic Obstructive Lung Disease stages II-IV), who were stratified by cachexia based on fat-free mass index (FFMI; in kg/m2: <16 for men and <15 for women) and compared with healthy control subjects (HCs). Body composition was determined by bioelectrical impedance analysis. Plasma concentrations and gene polymorphisms of interleukin 1beta (IL-1beta -511), IL-6 (IL-6 -174), and the tumor necrosis factor system (TNF-alpha -308 and lymphotoxin-alpha +252) were determined. Plasma C-reactive protein, leptin, and urinary pseudouridine (as a marker of cellular protein breakdown) were measured.
RESULTS: Fat mass, leptin, and pseudouridine were significantly different (P < 0.001) between noncachectic patients (NCPs) and cachectic patients (CPs: n = 35); the systemic inflammatory cytokine profile was not. NCPs had a body compositional shift toward a lower fat-free mass and a higher fat mass compared with HCs. CPs and NCPs had a greater systemic inflammatory response (P < 0.05) than did HCs, as reflected in C-reactive protein, soluble TNF-R75, and IL-6 concentrations. The overall distribution of the IL-1beta -511 polymorphism was significantly different between the groups (P < 0.05).
CONCLUSIONS: In COPD patients, who are characterized by an elevated systemic inflammatory response, cachexia is not discriminatory for the extent of increase in inflammatory status. This study, however, indicates a potential influence of genetic predisposition on the cachexia process.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16280439     DOI: 10.1093/ajcn/82.5.1059

Source DB:  PubMed          Journal:  Am J Clin Nutr        ISSN: 0002-9165            Impact factor:   7.045


  22 in total

1.  Genome-wide association analysis of body mass in chronic obstructive pulmonary disease.

Authors:  Emily S Wan; Michael H Cho; Nadia Boutaoui; Barbara J Klanderman; Jody S Sylvia; John P Ziniti; Sungho Won; Christoph Lange; Sreekumar G Pillai; Wayne H Anderson; Xiangyang Kong; David A Lomas; Per S Bakke; Amund Gulsvik; Elizabeth A Regan; James R Murphy; Barry J Make; James D Crapo; Emiel F Wouters; Bartolome R Celli; Edwin K Silverman; Dawn L DeMeo
Journal:  Am J Respir Cell Mol Biol       Date:  2010-10-29       Impact factor: 6.914

2.  Weight gain after lung reduction surgery is related to improved lung function and ventilatory efficiency.

Authors:  Victor Kim; Dana M Kretschman; Alice L Sternberg; Malcolm M DeCamp; Gerard J Criner
Journal:  Am J Respir Crit Care Med       Date:  2012-08-09       Impact factor: 21.405

3.  TNF-308 gene polymorphism is associated with COPD risk among Asians: meta-analysis of data for 6,118 subjects.

Authors:  Ping Zhan; Jing Wang; Shu-Zhen Wei; Qian Qian; Li-Xin Qiu; Li-Ke Yu; Yong Song
Journal:  Mol Biol Rep       Date:  2010-04-04       Impact factor: 2.316

4.  Chronic obstructive pulmonary disease: an update of treatment related to frequently associated comorbidities.

Authors:  Nicola J Sinden; Robert A Stockley
Journal:  Ther Adv Chronic Dis       Date:  2010-03       Impact factor: 5.091

Review 5.  Bench-to-bedside review: mobilizing patients in the intensive care unit--from pathophysiology to clinical trials.

Authors:  Alex D Truong; Eddy Fan; Roy G Brower; Dale M Needham
Journal:  Crit Care       Date:  2009-07-13       Impact factor: 9.097

6.  Associations of IL6 polymorphisms with lung function decline and COPD.

Authors:  J-Q He; M G Foreman; K Shumansky; X Zhang; L Akhabir; D D Sin; S F P Man; D L DeMeo; A A Litonjua; E K Silverman; J E Connett; N R Anthonisen; R A Wise; P D Paré; A J Sandford
Journal:  Thorax       Date:  2009-04-08       Impact factor: 9.139

Review 7.  Biomarkers for cancer cachexia: is there also a genetic component to cachexia?

Authors:  B H L Tan; D A C Deans; R J E Skipworth; J A Ross; K C H Fearon
Journal:  Support Care Cancer       Date:  2007-12-11       Impact factor: 3.603

Review 8.  Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update.

Authors:  Denis E O'Donnell; Shaw Aaron; Jean Bourbeau; Paul Hernandez; Darcy D Marciniuk; Meyer Balter; Gordon Ford; Andre Gervais; Rogers Goldstein; Rick Hodder; Alan Kaplan; Sean Keenan; Yves Lacasse; Francois Maltais; Jeremy Road; Graeme Rocker; Don Sin; Tasmin Sinuff; Nha Voduc
Journal:  Can Respir J       Date:  2007-09       Impact factor: 2.409

Review 9.  Updates on the COPD gene list.

Authors:  Yohan Bossé
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2012-09-18

10.  TNF-α is associated with loss of lean body mass only in already cachectic COPD patients.

Authors:  Tomas M L Eagan; Esteban C Gabazza; Corina D'Alessandro-Gabazza; Paloma Gil-Bernabe; Shinya Aoki; Jon A Hardie; Per S Bakke; Peter D Wagner
Journal:  Respir Res       Date:  2012-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.